Tirozin kinaz inhibitörü verilen kronik myeloid lösemi olgularında HBV serolojisi ve reaktivasyonunun retrospektif değerlendirilmesi
Küçük Resim Yok
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Giriş: Çalışmamızın amacı Tirozin Kinaz İnhibitörü (TKİ) kullanan Kronik Myeloid Lösemili (KML) vakalarda Hepatit B virüs (HBV) serolojisine hangi sıklıkla bakılmış olduğu ve seroloji bakılan hastalarda HBV reaktivasyonunun değerlendirilmesidir. Materyal Metod: İnönü Üniversitesi Turgut Özal Tıp Merkezi Hematoloji Bölümünde 2009-2019 yılları arasında KML ile takipli olup TKİ kullanan hastaların dosyaları retrospektif olarak incelendi. Bulgular: TKİ kullanan 132 KML hastasının retrospektif incelenmesinde HBsAg bakılan hasta sayısı 74 (% 56,06), HBsAg ve Anti-HBs birlikte bakılan hasta sayısı 73 (% 55,3), Anti-HBc IgG bakılan hasta sayısı 34 (%25,75), HBsAg ve AntiHBc IgG birlikte bakılan hasta sayısı yine 34 (% 25,75) olarak görülmüştür. HBsAg bakılan 74 KML hastasının hiçbirinde pozitiflik saptanmamıştır. Anti-HBc IgG bakılan 34 hastanın ise 10'unda (% 29,41) pozitiflik saptanmıştır. Bu 10 hastanın 3'ü çeşitli nedenlerden exitus olup takipleri yoktur. Geri kalan Anti-HBc IgG pozitif olan 7 hastanın takiplerinde HBV reaktivasyonu saptanmamıştır. Sonuç: TKİ kullanan KML hastalarında tedavi öncesi HBV serolojisi tarama oranı literatüre göre düşük bulunmuştur. Tedavi öncesinde her hastada; HBsAg, Anti- HBc IgG ve HBsAg veya Anti-HBc IgG pozitiflerde HBV DNA parametrelerinin bakılması gerekliliği ile ilgili takip eden hekimlere gerekli eğitimler verilip, farkındalık oluşturulmalıdır. HBV reaktivasyonu risk değerlendirilmesi yapılarak, risk durumuna göre profilaktik tedavinin değerlendirilmesi ve HBV enfeksiyon takibinin iyi yapılmasının gerekliliği üzerinde durulmalıdır. Anahtar Kelime: KML, TKİ, HBV, reaktivasyon
Introduction: The aim of our study is to evaluate the frequency of Hepatitis B virus (HBV) serology in patients with Tyrosine Kinase Inhibitor (TKI) and HBV reactivation in patients undergoing serology. Material Method: The files of patients using TKI who were followed up with CML in 2009-2019 at the Inonu University Turgut Ozal Medical Center, Hematology Department between 2009-2019 were analyzed retrospectively. Results: The number of patients who were treated with TKI using 132 CML HBsAg was 74 (56.06%), the number of patients who were HBsAg and Anti-HBs were 73 (55.3%), 34 (25.75%) were Anti-HBc IgG, The number of patients with HBsAg and Anti-HBc IgG together is 34 (25.75%). None of the 74 CML patients with HBsAg were positive. In 34 patients with Anti-HBc IgG, 10 (29.41%) were positive. 3 of these 10 patients are exitus for various reasons and have no follow-up. HBV reactivation was detected in the follow-up of 7 patients who remained Anti-HBc IgG positive. Conclusion: Screening rate of HBV serology before treatment was lower in CML patients using TKI compared to the literature. In each patient before immunosuppressive therapy; Necessary trainings should be provided and awareness should be raised regarding the necessity of monitoring HBV DNA parameters in HBsAg, Anti-HBc IgG and HBsAg or Anti-HBc IgG positives. HBV reactivation risk assessment should be made, and prophylactic treatment should be evaluated according to the risk status and the necessity of good HBV infection monitoring should be emphasized. Keyword: CML, TKI, HBV, reactivation,
Introduction: The aim of our study is to evaluate the frequency of Hepatitis B virus (HBV) serology in patients with Tyrosine Kinase Inhibitor (TKI) and HBV reactivation in patients undergoing serology. Material Method: The files of patients using TKI who were followed up with CML in 2009-2019 at the Inonu University Turgut Ozal Medical Center, Hematology Department between 2009-2019 were analyzed retrospectively. Results: The number of patients who were treated with TKI using 132 CML HBsAg was 74 (56.06%), the number of patients who were HBsAg and Anti-HBs were 73 (55.3%), 34 (25.75%) were Anti-HBc IgG, The number of patients with HBsAg and Anti-HBc IgG together is 34 (25.75%). None of the 74 CML patients with HBsAg were positive. In 34 patients with Anti-HBc IgG, 10 (29.41%) were positive. 3 of these 10 patients are exitus for various reasons and have no follow-up. HBV reactivation was detected in the follow-up of 7 patients who remained Anti-HBc IgG positive. Conclusion: Screening rate of HBV serology before treatment was lower in CML patients using TKI compared to the literature. In each patient before immunosuppressive therapy; Necessary trainings should be provided and awareness should be raised regarding the necessity of monitoring HBV DNA parameters in HBsAg, Anti-HBc IgG and HBsAg or Anti-HBc IgG positives. HBV reactivation risk assessment should be made, and prophylactic treatment should be evaluated according to the risk status and the necessity of good HBV infection monitoring should be emphasized. Keyword: CML, TKI, HBV, reactivation,
Açıklama
Anahtar Kelimeler
Hematoloji, Hematology
